Latest:
Chronic Myeloid Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings
Expert perspectives on key data in chronic myeloid leukemia from the ASCO 2023 and EHA 2023 Annual Meetings.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
James Melotek, MD
Latest:
Dr. Melotek on Cetuximab Added to Chemotherapy and Chemoradiation in Head and Neck Cancer
James Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses an analysis of a phase II study examining the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.
James P. Stevenson, MD
Latest:
Maintenance Strategies After Initial Chemotherapy for Non-Small Cell Lung Cancer
James P. Stevenson, MD, discusses optimization of drug and patient selection for maintenance therapies in NSCLC, and how it will continue to be a research focus in today's environment of value-based care.
James R. Berenson, MD
Latest:
Dr. Berenson Discusses Results from the CHAMPION-1 Trial
James R. Berenson, MD, founder, President and Medical and Scientific Director of the Institute for Myeloma and Bone Cancer Research, President of Oncotherapeutics, discusses the dose-escalation portion of the phase I/II CHAMPION-1 study looking at weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.